Daniel de Boer
Founder at PROQR THERAPEUTICS N.V.
Net worth: 1 M $ as of 2024-05-30
Profile
Daniel Anton de Boer is the founder of ProQR Therapeutics NV (founded in 2012) and holds the title of Chief Executive Officer & Executive Director.
He was also the founder of PC Basic B.V.
(founded in 2006) and held the title of Chief Executive Officer from 2006 to 2008.
Additionally, he was the founder of Running It (founded in 2005) and held the title of Chief Executive Officer from 2005 to 2011.
Mr. de Boer is also the founder of Amylon Therapeutics BV.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PROQR THERAPEUTICS N.V.
0.86% | 2023-12-30 | 705,309 ( 0.86% ) | 1 M $ | 2024-05-30 |
Daniel de Boer active positions
| Companies | Position | Start |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Founder | 2012-02-20 |
Former positions of Daniel de Boer
| Companies | Position | End |
|---|---|---|
| Running It | Chief Executive Officer | 2011-08-31 |
| PC Basic B.V. | Chief Executive Officer | 2008-01-31 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| Private companies | 3 |
|---|---|
| PC Basic B.V. | |
| Running It | |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Daniel de Boer
